Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines

We describe simultaneous influenza and mRNA COVID-19 bivalent booster vaccine administration between August 31-December 31, 2022, among persons aged ≥6 months in the Vaccine Safety Datalink (VSD) by COVID-19 bivalent booster vaccine type, influenza vaccine type, age group, sex, and race and ethnicity. Of 2,301,876 persons who received a COVID-19 bivalent booster vaccine, 737,992 (32.1%) received simultaneous influenza vaccine, majority were female (53.1%), aged ≥18 years (91.4%), and non-Hispanic White (55.7%). These findings can inform future VSD studies on simultaneous influenza and COVID-19 bivalent booster vaccine safety and coverage, which may have implications for immunization service delivery.PMID:37599140 | DOI:10.1016/j.vaccine.2023.08.023

Source: Vaccine - August 20, 2023 Category: Allergy & Immunology Authors: Tat'Yana A Kenigsberg Kristin Goddard Kayla E Hanson Ned Lewis Nicola Klein Stephanie A Irving Allison L Naleway Bradley Crane Tia L Kauffman Stanley Xu Matthew F Daley Laura P Hurley Robyn Kaiser Lisa A Jackson Amelia Jazwa Eric S Weintraub Source Type: research